MYCOF News and Press, New Age Brands From 05/03/21

Positioned as Leader in Emerging Psychedelic Therapeutics Market through Robust IP Portfolio, Novel Clinical Trials and Evolving Proprietary Technology Strengthened Balance Sheet with Approximately $30 Million in Capital Raised Subsequent to the Year-End Announced Appointm...

New York-based MindMed will begin trading on the Nasdaq today, becoming the second psychedelic company ever to go public on a major American exchange. Shroom drug developer Compass Pathways (CMPS) debuted only six months ago, while another "drug growth platform,"called Atai Life Sciences, fil...

DENVER, April 26, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA ) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of altern...

Palm Beach, FL – April 22, 2021 – Global Psychedelic and Psilocybin Drugs market is growing rapidly due to the increasing number of depression cases and rising special designation from the regulatory authorities to the company to expedite the development process of medicines. ...

As an urgent public mental health crisis forces research institutions and governments to seriously examine unconventional mental health solutions, psychedelic assisted therapies are showing huge potential. Now, biotech companies have seen the opportunity, and psychedelics comp...

DENVER, April 13, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-...

This is Psychedellux – the week’s top news for psychedelic stocks. Tryp Therapeutics (OTCQB: TRYPF) began trading this week on the OTCQB Venture Market under the symbol “TRYPF” and will continue to trade on the Canadian Securities Exchange under t...

Mydecine Innovations Group (OTC: MYCOF) has announced its four lead novel drug candidates as it prepares for its Pre-Investigational New Drug (IND) meetings with the FDA and Health Canada. Mydecine said it believes that these drug candidates are unique and patentable in the Un...

DENVER, April 07, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group™(CSE:MYCO)(OTC:MYCOF)(FSE: 0NFA)(“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance ...

DENVER, April 07, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-...